Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ddg.12049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Erlotinib-induced Perioral Lesions Resembling Scleroderma.
Acta Dermatovenerol Croat
November 2024
Constantin A. Dasanu MD, PhD, Lucy Curci Cancer Center, Eisenhower Health, 39000 Bob Hope Dr, Rancho Mirage, CA 92270 , USA;
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is currently used in the therapy of several solid malignancies. This agent has been associated with several dermatological side-effects, the most common being papulo-pustular acneiform rash. Herein we describe a unique skin effect in a patient treated with erlotinib for non-small cell lung cancer.
View Article and Find Full Text PDFEffective Management of Severe Epidermal Growth Factor Receptor Inhibitors-Induced Papulopustular Eruption With Low-Dose Isotretinoin and Corticosteroids.
Cureus
November 2024
Oncologic Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.
Epidermal growth factor receptor inhibitors (EGFRi) are approved for treating various cancers. Given that EGFR signaling is crucial for normal skin growth and repair, inhibiting this pathway can disrupt skin homeostasis and integrity. Although generally well tolerated, molecularly targeted therapies can lead to skin-related adverse effects that significantly impact patients' quality of life, often resulting in treatment interruptions.
View Article and Find Full Text PDFDrug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist.
Am J Gastroenterol
January 2025
INFINY Institute, Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, F-54500 Vandœuvre-lès-Nancy, France.
Article Synopsis
- Drug-induced acne is a skin problem that can happen when people take certain medicines, especially to treat inflammatory bowel disease (IBD).
- Medicines like corticosteroids and Janus kinase inhibitors (JAKi) can make acne worse or cause new breakouts.
- The review gives tips for doctors on how to help patients manage this acne so they don't stop their important treatment for IBD.
Article Synopsis
- Papulopustular eruptions are the most common skin side effects of epidermal growth factor receptor inhibitor (EGFRI) therapy.
- Topical corticosteroids and oral tetracyclines are commonly used to treat these eruptions, but both have limitations in effectiveness and potential side effects.
- A case study shows that topical aprepitant (HT-001) 2% cream may provide a rapid and effective response for treating EGFRI-induced skin toxicities.
Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.
Acta Derm Venereol
August 2024
Department of Dermatology, Seoul National University Hospital, Seoul, Korea; Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; Institute of Human-Environmental Interface Biology, Medical Research Center, Seoul National University, Seoul, Korea; Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.
Article Synopsis
- * The most common skin toxicity reported was papulopustular rash (74.3%), with other issues including pruritus (61.1%), xerosis (52.4%), and paronychia (39.6%), with younger males showing more severe cases.
- * Skin toxicities resulted in treatment adjustments for 26.7% of patients, particularly with second-generation inhibitors, emphasizing the need for effective management to optimize treatment outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!